Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XDTV | ISIN: NL0010696654 | Ticker-Symbol: UQ1
Tradegate
24.04.25
18:08 Uhr
13,205 Euro
+0,515
+4,06 %
1-Jahres-Chart
UNIQURE NV Chart 1 Jahr
5-Tage-Chart
UNIQURE NV 5-Tage-Chart
RealtimeGeldBriefZeit
13,02013,15518:17
13,00513,13518:16

Aktuelle News zur UNIQURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiUniQure stock holds $70 target, buoyed by FDA breakthrough nod5
MoFDA grants breakthrough status to uniQure's Huntington's disease therapy2
17.04.uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday6
17.04.Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?2
17.04.uniQure jumps on FDA breakthrough tag for Huntington's disease drug2
17.04.HotStocks USA: +45 % bei uniQure2
17.04.uniQure-Aktien steigen nach FDA-Durchbruchtherapie-Status15
17.04.uniQure shares soar on FDA breakthrough therapy designation1
UNIQURE Aktie jetzt für 0€ handeln
17.04.uniQure Inc.: uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease719~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics...
► Artikel lesen
16.04.uniQure N.V. - 8-K, Current Report1
01.04.Chardan sets uniQure stock Buy rating, $38 target on gene therapy potential-
27.02.uniQure GAAP EPS of -$4.92 misses by $0.97, revenue of $27.1M misses by $12.3M5
27.02.uniQure N.V. - 10-K, Annual Report-
27.02.uniQure Inc.: uniQure Announces 2024 Financial Results and Highlights Recent Company Progress502~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential...
► Artikel lesen
27.02.uniQure N.V. - 8-K, Current Report-
07.02.uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years9
03.02.uniQure macht Fortschritte bei Gentherapie-Studie für Morbus Fabry10
03.02.uniQure Inc.: uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease302~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~ ~ Company expects to initiate enrollment of second dose cohort in the...
► Artikel lesen
30.01.uniQure Inc.: uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS317~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~ ~ Company Expects to Initiate Enrollment of Second Dose...
► Artikel lesen
13.01.Here's Why uniQure N.V. (QURE) Is Skyrocketing4
Seite:  Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1